Forefront Analytics, LLC
Long book
$110.0M
Q1 2026
Positions
39
Top-10 weight
87%
concentration
Last quarter
+12.8%
SPY +14.8%
Turnover
26%
of book per quarter
Strategy in plain words
auto-generated from filingsForefront Analytics, LLC is a wealth-management firm allocating client money, running a $110.0M US long book across 39 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: ISHARES TRUST ISHARES ESG AW, ISHARES INC ISHARES ESG AWAR, VANGUARD FTSE EMERGING MARKE, ISHARES CORE HIGH DIVIDEND E, NUVEEN ESG LARGE-CAP VAL ETF.
Over the last 9 quarters its long book ran on average 0.1pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. Its holdings are mechanical (indexing / client flows), so position changes carry no stock-picking signal.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+1.0%
Q2 2024
+7.1%
Q3 2024
-2.9%
Q4 2024
+2.2%
Q1 2025
+8.0%
Q2 2025
+7.0%
Q3 2025
+2.9%
Q4 2025
+1.1%
Q1 2026
+12.8%
Sector allocation
Healthcare 33%
Technology 29%
Financials 22%
Other 7%
Industrials 7%
Consumer staples 3%
Long book by quarter
What does Forefront Analytics, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| NVDA NVIDIA CORP | Technology | 14.2K | $2.5M | 2.3% | +1.9% |
| JPM JPMORGAN CHASE & CO | Financials | 5.0K | $1.5M | 1.3% | +48.6% |
| DE DEERE & CO | Industrials | 1.1K | $640K | 0.6% | +0.3% |
| UNH UNITEDHEALTH GROUP INC | Financials | 2.0K | $537K | 0.5% | +36.6% |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 6.6K | $526K | 0.5% | +7.5% |
| ABT ABBOTT LABORATORIES | Healthcare | 5.0K | $518K | 0.5% | +34.3% |
| MDT MEDTRONIC PLC | Healthcare | 5.3K | $461K | 0.4% | +24.3% |
| INCY INCYTE CORP | Healthcare | 4.2K | $398K | 0.4% | -18.6% |
| PFE PFIZER INC | Healthcare | 13.1K | $368K | 0.3% | -31.5% |
| OTF BLUE OWL TECHNOLOGY FINANCE | — | 29.7K | $367K | 0.3% | New |
| REGN REGENERON PHARMACEUTICALS | Healthcare | 460 | $355K | 0.3% | +7.7% |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 579 | $285K | 0.3% | -1.2% |
| DHR DANAHER CORP | Technology | 1.3K | $244K | 0.2% | +40.8% |
| PM PHILIP MORRIS INTERNATIONAL | Consumer staples | 1.4K | $240K | 0.2% | +0.9% |
| NKTX NKARTA INC | Healthcare | 43.8K | $92K | 0.1% | +7.7% |
| ZURA ZURA BIO LTD | Healthcare | 14.9K | $89K | 0.1% | -23.9% |
| GERN GERON CORP | Healthcare | 55.1K | $82K | 0.1% | +7.4% |
| ANNX ANNEXON INC | Healthcare | 14.2K | $79K | 0.1% | +7.7% |
| CTMX CYTOMX THERAPEUTICS INC | Healthcare | 12.5K | $59K | 0.1% | -33.3% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 13, 2026 | 39 | $110.0M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 47 | $113.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 21, 2025 | 46 | $103.8M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR/ARESTATEMENT | Aug 14, 2025 | 47 | $89.5M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 24, 2025 | 74 | $117.1M | SEC ↗ | |
| Q1 2025 | 13F-HR | May 13, 2025 | 72 | $86.9M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 113 | $215.0M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 114 | $212.0M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 15, 2024 | 114 | $208.9M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 113 | $206.2M | canonical | SEC ↗ |